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T. BRATEL*, A. WENNLUND~ AND K. CARLSTROM* 
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Gynaecology, Huddinge University Hospital, Kizrolinska Insfifufe, Sweden 
We studied the effects of chronic nocturnal hypoxaemia due to obstructive sleep apnoea syndrome (OSAS) on the 
hypothalamic-pituitary-thyroid and hypothalamic-pituitary-testicular axes and on catecholamine and cortisol 
secretion. We investigated whether hormones other than catecholamines may serve as markers for chronic hypoxic 
stress and the possible effects of nasal continuous positive airway pressure (nCPAP) treatment on endocrine 
status. 
Nocturnal oximetry was performed in 16 male patients with OSAS diagnosed by polysomnography, immediately 
before nCPAP treatment and in 11 of the patients the oximetry was repeated after 7 months of nCPAP therapy. 
Plasma and urinary catecholamines, luteinizing hormone (LH), testosterone, cortisol, thyroid stimulating hormone 
(TSH), prolactin (PRL), and the response of TSH and PRL to a thyroid releasing hormone (TRH) challenge test 
were measured immediately before and after 7 months of nCPAP treatment. 
Subnormal LH and TSH and elevated serum cortisol as well as increased nocturnal urinary norepinephrine levels 
were found in patients prior to treatment; otherwise endocrine values were normal. There was a significant 
correlation between low pretreatment nocturnal arterial oxygen saturation and high plasma and urinary norepine- 
phrine levels. The nCPAP treatment caused significant reduction in serum prolactin and TSH, and significant 
reduction in plasma epinephrine and urinary norepinephrine. The reduction in serum TSH and urinary norepine- 
phrine was most pronounced in the subjects with the worst pretreatment nocturnal hypoxaemia. No other significant 
changes were found in basal hormone levels. The response to TRH challenge was normal before and after treatment 
and was not influenced by CPAP therapy. 
OSAS is associated with elevated catecholamine and cortisol and decreased TSH and LH levels but a normal 
response to TRH challenge and a normal androgen status. Apart from catecholamines, none of the hormones 
studied is likely to serve as a specific marker for chronic hypoxic stress. 
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Introduction 
There are often striking clinical resemblances between 
obstructive sleep apnoea syndrome (OSAS) and hypo- 
thyroidism (1). Elevated thyroid stimulating hormone 
(TSH) levels have also been found in patients suffering from 
other acute non-fatal non-thyroidal illnesses (2). In con- 
trast, reduced secretion of basal TSH has been found in 
fatal non-thyroidal diseases (3,4). The effects of critical 
illness on stimulated TSH levels are varied (3,4). However, 
whether OSAS is accompanied by disturbances to the 
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hypothalamic-pituitary-thyroid axis has, to our knowl- 
edge, not been previously studied. Furthermore, treatment 
of hypothyroidism without discovery and treatment of any 
possible concomitant OSAS may lead to dangerous cardiac 
complications (5). Early detection of hypothyroidism is 
therefore probably of clinical importance in OSAS. Stimu- 
lation of TSH by thyroid releasing hormone (TRH) chal- 
lenge may be a means of detection of subclinical defects in 
thyroid function (6). Subclinical hypothyroidism is defined 
as supranormal TSH increase in conjunction with normal 
levels of thyroid hormones (7). 
Reduced secretion of testosterone (T) has been noted in 
men with OSAS and indeed severe (OSAS) is frequently 
associated with sexual and emotional disturbances such as 
decreased libido and depression (8,9). However, it is not 
known whether the hypothalamic-pituitary-thyroid axis 
and hypothalamic-pituitary-testicular axis are affected by 
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the same mechanisms in OSAS. Therefore gonadotropins TABLE 1. Anthropometric, lung function and sleep study 
and sex hormones were also measured in the present study. data in 16 patients 
Increased excretion of catecholamines in OSAS has been 
noted in previous studies (10,ll) and has been found to be 
primarily related to nocturnal hypoxaemia rather than to 
the frequency of apnoeas (10,12). The catecholamine levels 
may thus be regarded as markers of the chronic hypoxic 
stress induced by OSAS. Acutely augmented catecholamine 
secretion is associated with increased TSH secretion in 
healthy human subjects (13,14). However, it has not been 
elucidated whether a long-term elevation of catecholamine 
secretion due to OSAS is accompanied by increases in TSH 
secretion or in any other pituitary hormone. 
Mean f SEM Range 
Long-term nCPAP treatment effectively restores normal 
nocturnal breathing, nocturnal oxygenation and sleep pat- 
terns and most probably increases life expectancy even in 
severe OSAS (15). Our knowledge is, however, limited with 
regard to the effects of long-term nCPAP therapy on 
pituitary function. 
Age (years) 51.3 3.7 26-74 
BMI kg (mg2)-’ 32.0 1.6 25.0-46.7 
Syst. BP mmHg 143.8 4.3 110-170 
Diast. BP mmHg 87.5 2.5 65-105 
FEV, %P 84.6 5.9 48-l 11 
FVC %P 81.6 5.4 47-104 
PaO, kPa 10.9 0.4 74-13.4 
PaCO, kPa 5.6 0.1 5.0-6.8 
Apnoea index 43.3 4.7 20-65 
ODI 39.2 7.0 8.693.3 
MSaO, (%) 91.4 0.9 85.6951 
MminSaO, (%) 85.2 1.6 75.0-91.6 
NNOS (“Yo) 69.0 3.7 50.0-86.0 
The present investigation was undertaken to study the 
possible effects of nocturnal hypoxaemia on catecholamines 
and cortisol secretion as well as the hypothalamic- 
pituitary-thyroid and hypothalamic-pituitary-testicular 
axes and the effects of nCPAP treatment on endocrine 
status. Furthermore, we wanted to find out which hor- 
mones could serve as specific markers of chronic hypoxic 
stress. 
BMI=body mass index: 20-25 kg (m”) - ’ = normal; 
25-30 kg (m2) - ’ = overweight; 130 kg (m’) - ’ =obese; 
FEV, %P=forced expiratory volume in 1 s in % predicted; 
FVC %P=forced vital capacity in % predicted; 
ODI=oxygen desaturation index; NNOS=nadir nocturnal 
arterial oxygen saturation; MSaO,=mean nocturnal 
arterial oxygen saturation; MminSaO, = mean minimal 
nocturnal arterial oxygen saturation. 
Patients and Methods 
SUBJECTS 
Sixteen men with moderate to severe OSAS were included 
in the study. Anthropometric data are given in Table 1. All 
patients were heavy snorers and suffered from moderate to 
severe daytime somnolence. Three were treated for hyper- 
tension with diuretics or vasodilators. None suffered from 
labile diabetes mellitus, overt liver disease, severe alcohol 
abuse or unstable psychiatric disorder. No patient received 
any hormonal treatment. All patients gave their informed 
consent and the study was performed in accordance with 
the guidelines of the ethical committee of the Huddinge 
University Hospital. Data on serum and plasma hormones 
were compared with those obtained from 22 healthy men 
matched for age and as far as possible for body mass index 
(BMI). Urinary catecholamines were related to our routine 
clinical reference limits. 
SLEEP STUDIES 
All patients were subjected to a daytime polysomnography 
after one night’s sleep deprivation. Standard sleep vari- 
ables, including an electroencephalogram (P,-F,/T,-C,), 
electro-oculogram and a submental electromyogram were 
recorded with surface electrodes (16). Respiratory move- 
ments of the thorax and the abdomen were monitored with 
pneumobelts connected to pressure transducers (Respitrace 
Corp., UFI. Morro Bay, CA, U.S.A.). Nasal and oral 
airflow was determined by thermistors. The arterial oxygen 
saturation (SaO,) was traced by a finger pulse oximeter 
(Radiometer A/S, Copenhagen, Denmark). All variables 
were recorded by means of a polygraph. Apnoeas with a 
duration of at least 10 s were recorded and the number of 
apnoeas per sleep hour (apnoea index) was determined. In 
this way the patients’ OSAS diagnosis was confirmed 
but data collected in conjunction with the daytime 
polysomonography were not utilized for statistical analysis. 
After 6-12 months, the patients were subjected to a full 
night’s pulse oximetry (Radiometer A/S). An arterial oxy- 
gen desaturation of at least 4% below the stable supine 
baseline level was considered significant. The oxygen 
desaturation index (ODI) was defined as the number of 
significant desaturations per hour of nocturnal recording. 
The mean arterial oxygen saturation (MrSaOJ for the 
whole night was estimated. The minimal SaO, during each 
desaturation episode was recorded, and mean minimal 
arterial oxygen saturation (MminSaO,) for the whole night 
was calculated. The nadir nocturnal SaO, (NNOS) was 
recorded. All oximetry tracings were analysed by the same 
observer (T.B.). 
PHYSIOLOGICAL AND LABORATORY 
INVESTIGATIONS 
The patients underwent a clinical examination including a 
supine blood pressure measurement on the day before the 
nocturnal oximetry. A 12-h nocturnal urinary collection for 
catecholamine assay was performed simultaneously with 
the pulse oximetry. Arterial blood gases were drawn on the 
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TABLE 2. Basal serum levels of steroid and pituitary hormones, plasma (P) and urinary (U) 
catecholamines in 16 untreated OSAS patients and 32 healthy controls matched for age and BMI 
Patients Controls 
Age (years) 51.3 * 2.7 51.5 f 2.5 
BMI (kg (m2)- ‘) 32.0 5 1.4 29.6 zt 1.4 
T (nmol 1 - i) 18.3 f 1.3 18.5 f 1.1 
SHBG (nmol 1 - ‘) 15.0 Zt 1.9 (n=4) 33.1 f 2.7 
Free T (nmol l- ‘) 0.51 Zt 0.05 (n=4) 0.37 ik 0.03 
LH (VI-‘) 3.0 (l-5): 6.7 (2-13) 
Cortisol (nmol I- ‘) 489 =!I 39* 391 f 22 
PRL &gll’) 6.5 (S&18.0) 6.0 (2.8-27.9) 
TSH (Ul-‘) 1.5 (0.7-3.0)* 2.0 (1.0-3.1) 
P-E (nmol I- ‘) 0.16 (0.05-0.59) 0.10 (0.05-0.20) 
P-NE (nmol 1 - ‘) 2.10 (0+30-5.50)* 1.25 (0.80-l .70) 
U-E (nmol l- ‘) 10 (746) <30” 
U-NE (nmol 1 - ‘) 160 (68-447) ~178~ 
Significant differences between patients and controls are denoted by *= PcO.05; *= P<O.OOl. 
QZlinical reference limits. 
For abbreviations, see text. 
following morning (ABL 520, Radiometer A/S). Venous 
blood samples for hormone analysis were drawn at about 
0800 h after an overnight fast. Serum and plasma were 
separated after centrifugation and stored at - 20°C until 
analysis. A thyroid releasing hormone (TRH) stimulation 
test was performed after breakfast with i.v. injection of 
2OOpg of TRH (Thyrefact@, Hoechst A.G., Frankfurt, 
Germany). Venous blood samples for analysis of thyroid 
stimulating hormones (TSH) and prolactin (PRL) in serum 
were drawn immediately before and 20 and 60 min after 
injection of TRH. A normal TRH response in males above 
40 years of age is characterized by an increase of 2 100% in 
TSH and PRL 20 min after injection of TRH (17,18). The 
response to the TRH stimulation is indicated as the maxi- 
mum increase in hormone concentration above the basal 
level (the delta value). 
Patients started their nasal CPAP treatment the night 
following the first night’s oximetry. The CPAP pressure was 
increased stepwise over 2-4 nights until the oximetry trac- 
ing was free from desaturations. After 610 months of 
regular nocturnal nCPAP treatment, the patients under- 
went a second nocturnal oximetry, taken during ongoing 
nCPAP treatment, and all the above mentioned measure- 
ments were repeated. All statistical analysis was based 
solely on hormonal measurements and other data obtained 
in conjunction with the oximetries immediately before and 
after an average 7 months of therapy. Adherence to the 
treatment regime was ascertained by open questioning and 
clinical assessment of increased daytime alertness. 
HORMONE ASSAYS 
Serum concentrations of PRL, luteinizing hormone (LH), 
testosterone (T) and cortisol were detected by radioimmu- 
nological methods and sex hormone-binding globulin 
(SHBG) by an immunoradiometric method using commer- 
cial kits obtained from Diagnostic Products Corp., Los 
Angeles, CA (PRL, LH, T) and Orion OY, Turku, Finland 
(SHBG, cortisol). TSH was measured by a fluoroimmuno- 
assay using a commercial kit from Wallac OY, Turku, 
Finland. Catecholamines in plasma and urine were deter- 
mined by a modified high pressure liquid chromatography 
technique (19,20). 
Practical detection limits and within and between assay 
coefficients of variation were: TSH 0.4 U I- I, 5.0% and 
7.2%; PRL 1.4 pg l- ‘, 7% and 11%; LH 1.2 U I- I, 7% and 
lO%;TO~lnmoll-‘, 6%and 10%; SHBG6nmoll-‘, 5% 
and 11%; cortisol 11 nmol l-i, 5% and 7%. For plasma 
catecholamines, the total coefficient of variation (CV) was 
18% at about 25 nmol 1 - i and for urinary catecholamines 
total CV was about 5% at the upper reference level (Table 
2). Values below the practical detection limit were set to 
l.OUl-’ for LH. 
Apparent concentrations of free testosterone were calcu- 
lated from values for total T and SHBG and a fixed 
albumin concentration of 42 g I- ’ by successive approxi- 
mation using a computer program based upon an equation 
system derived from the law of mass action (21). 
STATISTICAL ANALYSIS 
Normally distributed variables are expressed as arithmetic 
means and SEM; otherwise as median and range. Results 
before and after nCPAP treatment were compared by 
paired t-test or Wilcoxon’s signed-rank test according to 
distribution. Correlations between variables were assessed 
by Spearman’s rank correlation test or simple linear regres- 
sion according to distribution. A P-value of below 0.05 was 
considered significant. 
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TABLE 3. Basal serum levels of steroid and pituitary hormones, increments in pituitary hormones 
following TRH challenge (delta-values), plasma (P) and urinary (U) catecholamines, in 11 patients 
with OSAS before and after 7 months of CPAP treatment 
Before treatment After treatment 
T (nmol 1 - ‘) 17.7 z!z 1.8 16.7 f 2.1 
SHBG (nmol 1 - ‘) 13.7 5 1.9 (n=3) 27.1 & 6.5 (n=7) 
Free T (nmol 1 - ‘) 0.50 f 0.07 (n = 3) 0.43 f 0.04 (n=7) 
LH (Ul-‘) 3.0 (l-5)$ 4.0 (l-7)+ 
Cortisol (nmol I- ‘) 510 * 38* 431 L!Z 36 
P-E (nmol 1 - ‘) 0.21 (0.07-059) 0.11 (0.05-0.36)” 
U-E (nmol 1 - ‘) 10.0 (74-46.0) 10.0 (4.0-20.0) 
P-NE (nmol 1 - ‘) 2.15 (l.l-5*5)+ 2.00 (1.30-4*40)+ 
U-NE (nmol 1 - ‘) 236 (119-447) 136 (66-281)” 
TSH (Ul-‘) 1.4 (0.7-2.6)* 1.1 (0.7-2.2)+$ 
Delta TSH (U l- ‘) 6.4 (2.8-l 1.3) 6.3 (2.9-13.6) 
PRL @gl-‘) 6.7 f 0.5 5.1 f 0.3” 
Delta PRL (ug 1 - ‘) 18.0 (7.0-34.0) 16.1 (7.0-35.0) 
Significant differences between pre- and post-treatment values are denoted by D=P<0.05. Significant 
differences between patients and controls are denoted by *=P<O.O5; +=P<O.Ol; +=P<O.OOl. 
For abbreviations, see text. 
Results 
The 16 patients had a diastolic blood pressure close Endocrine data for all 16 patients before treatment and 
the upper limit of normal. In eight subjects the diastolic in matched controls, data on urinary catecholamines and 
blood pressure was at or above 90 mmHg. Daytime clinical reference values are given in Table 2. The patients 
polysomnography showed a mean apnoea index of had significantly elevated pretreatment levels of serum 
43.3 f 3.6 h - ‘. The nocturnal oximetry immediately before cortisol and significantly decreased TSH levels compared to 
nCPAP treatment showed a mean oxygen desaturation the controls. The hormonal response to TRH challenge 
index of 39.3 & 5.3 h- ‘. Four patients suffered from a was normal. The patients had significantly elevated plasma 
moderately restrictive impairment of ventilation exhibiting NE levels compared to the controls and their median 
a forced vital capacity of less than 80% of predicted value urinary NE excretion was close to the upper clinical 
(FVC %P). However, the group as a whole had a FVC %P reference limit. Normal T but decreased LH values were 
within the normal range (Table 1). Daytime blood gases found before treatment. For technical reasons SHBG could 
were within the normal range (Table 1). However, three only be determined in four patients before and in seven 
patients were slightly to moderately hypoxaemic (PaO, after nCPAP treatment. Low SHBG-values and free T 
range: 74-9.9 kPa) and one had an increased PaCO, within the upper range of normal were observed before 
(6.8 kPa). treatment. 
After an average interval of 7 months, 10 patients treated 
with a mean CPAP pressure of 8.25 (range: 5-12.5) cm of 
H,O were restudied. Nocturnal oximetry during CPAP 
treatment showed that in most of the patients there were no 
significant desaturations and all patients had an ODI of less 
than 5 h- I. Another patient underwent uvolo-pharyngo- 
palato-plastic (UPPP) surgery. Assessment at about 6 
weeks after the operation with a static-charge-sensitive bed 
showed that this apnoea index was less than 5 h- ‘. His 
hormonal measurements, performed about 2 months post- 
operatively, were included within the study. Eleven subjects 
were thus restudied. 
The mean blood pressure, forced expiratory volume in 1 s 
(FEV,), forced vital capacity (FVC), and body mass index 
(BMI) remained unaltered after 7 months of CPAP treat- 
ment. For technical reasons these variables were measured 
in only eight individuals after treatment. All patients 
Endocrine data for the 11 patients subjected to treatment 
are given in Table 3. The treatment caused significant 
suppression in plasma E and in urinary NE and in basal 
TSH and PRL. No other significant effects of the treatment 
on pituitary hormones were noted. Median values for LH 
were still significantly lower in the patients following treat- 
ment than in healthy subjects. There was no significant 
difference in SHBG between treated patients and controls. 
However, in the few patients where SHBG levels before and 
after treatment were available (n = 3) these low values were 
not changed by the treatment. The treatment reduced 
s-cortisol in 75% of the patients. Although this change 
failed to attain significance, the level of cortisol was now 
normal, compared to controls. The median plasma NE was 
still close to the upper clinical reference limit, while the 
corresponding value for urinary NE was now clearly below 
this limit. 
experienced a reduction in their daytime somnolence due to 
the CPAP treatment. 
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TABLE 4. Correlations between indices of pretreatment 
nocturnal respiratory disturbances on the one hand and 
pretreatment physiological and hormonal variables as well 
as the treatment induced change in hormonal levels on the 
other 
NNOS MminSaO, 
(4 (4 
ODI 
(4 
BMI 1 
Diastol. BP 
FEV, %P 
P-norepinephrine 
P-epineprhine 
U-norepinephrine 
% ch. TSH 
% ch. U-norepin. 
- 0.71* 
- 067+ 
0.63* 
- 0.60* 
- 055 
- 0.75* 
0.47 
- 0.93 
- 0.66* 
- 0.66* 
0.66* 
- 0.71* 
- 0.63* 
- 0.72* 
0.70* 
1 .oo* 
0.76+ 
0.72’ 
- 0.68* 
0.58* 
0.57* 
0.62( *) 
- 0.36 
- 0.83 
BMI 1 =body mass index before treatment; NNOS=nadir 
nocturnal arterial oxygen saturation; MminSaO, =mean 
minimal arterial oxygen saturation; ODI=oxygen desatur- 
ation index; FEV, %P=forced expiratory volume in 1 s in 
% predicted; % ch.= the percentage change of a variable 
induced by 7 months of CPAP treatment; TSH=thyroid 
stimulating hormone. 
Correlations between pretreatment indices of nocturnal 
hypoxaemia on the one hand and BMI, blood pressure and 
endocrine data on the other are given in Table 4. Before 
treatment, indices of severe nocturnal hypoxaemia (low 
MminSaO,, reduced NNOS and high ODI) were associated 
with high catecholamine levels, augmented BMI and high 
diastolic blood pressure. A low NNOS tended to correlate 
with a low total serum testosterone level (rE0.52, CO.06). 
High pretreatment serum TSH values correlated with 
increased pretreatment P-NE levels (rz0.59, PcO.05). 
The largest post-treatment reduction in urinary NE and 
in serum TSH was noted in the patients with the worst 
pretreatment nocturnal hypoxaemia (Table 4) and these 
changes correlated with each other (rx0.85, PcO.05). 
Serum T and SHBG values were positively correlated in the 
patients when pre- and post-treatment values were com- 
bined (rz0.70, PcO.05; IZ= 1 I) and also in controls (rE0.53, 
WO.01). 
Discussion 
Elevated serum cortisol and plasma NE values in the 
presence of low serum TSH and LH levels were the main 
endocrine findings in untreated OSAS patients compared to 
control; however, the levels of pituitary hormones were still 
within normal range. 
The increased nocturnal catecholamine secretion in 
OSAS is related to the degree of nocturnal hypoxia caused 
by this disease (10,12). In the present study correlations 
between pretreatment nocturnal respiratory disturbances 
and pretreatment endocrine variables were found only for 
plasma and &nary catecholamines. Thus, it is rather 
unlikely that hormones other than catecholamines serve as 
specific markers for chronic hypoxic stress. Reduced noc- 
turnal epinephrine but not norepinephrine levels following 
8 days of nCPAP treatment have been reported previously 
(11,22). Such short-term treatment may be insufficient to 
regulate sleep patterns completely in OSAS (23,24) and 
thereby stabilize the central mechanisms regulating cate- 
cholamine secretion. Long-term nCPAP therapy has been 
found to reduce the level of plasma and urinary metabolites 
of norepinephrine (25). Significantly reduced levels of both 
catecholamines following nCPAP treatment were found in 
our study. The changes in nocturnal urinary norepinephrine 
were most pronounced in the subjects who were most 
severely affected by their disease. The reduction in nor- 
epinephrine which, to a certain extent, was paralleled by 
reduction in TSH in the present study, may reflect reduced 
chronic hypoxic stress following long-term nCPAP treat- 
ment. The post-treatment normalization of serum cortisol 
in our study group may be due to a long-term reduction of 
the level of stress in general. 
Previous large cross-sectional studies have not shown 
an increased incidence of overt hypothyroidism in OSAS 
(8,26). However, thyroid status was assessed by thyroxin 
and thyroxin-binding globulin in only one of these two 
studies (8) and in the other the sensitivity of the radio- 
immunoassay for TSH was not indicated (26). Despite the 
high sensitivity for low levels of TSH of the immunoassay 
employed in the present study (3), no case of overt or 
subclinical hypothyroidism was found, Rather than being 
elevated, the TSH levels in our patients were lower than in 
the controls and the response to TRW challenge was 
perfectly normal before and after treatment (17). This may 
reflect an altered setting of the thyreostat in these patients. 
In the current study CPAP treatment caused a further small 
reduction in basal TSH. There may be possible factors 
contributing to this effect of long-term CPAP therapy. 
Firstly, it may imply that a subclinical thyroid malfunction 
at the hypothalamic level was present, at least in the 
subjects with the worst pretreatment nocturnal hypoxaemia 
(8,9). Secondly, the normal nocturnal increase in TSH and 
PRL secretion (27,28) is probably disturbed in OSAS. 
Disturbances of the normal sleep-related hormonal surge 
may result in increased TSH secretion during wakefulness 
(28). CPAP treatment in many cases restores normal sleep 
architecture and circadian rhythms (29), probably resulting 
in increased nocturnal PRL and TSH secretion, which in 
turn may contribute to the reduced daytime basal levels of 
these hormones found after treatment in our study. Thirdly, 
the reduction in catecholamine secretion after nCPAP- 
treatment may directly influence pituitary function or may 
indirectly cause reduced TSH production via its effects on 
the thyroid gland (13,14). 
Normal LH levels have previously been demonstrated in 
patients with OSAS or chronic obstructive lung disease, but 
usually together with low levels of T (8,9,30,31). However, 
in contrast to previous studies, normal total and free T 
levels combined with subnormal LH concentrations 
were found in our patients, although the lowest total T 
levels were noted in subjects with the worst nocturnal 
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hypoxaemia. The findings of low LH levels in the presence 
of a normal T:SHBG ratio in the patients after treatment 
excludes an increased testicular negative feedback as the 
cause of the low LH levels. 
Contrary to previous reports (8,9), nCPAP treatment did 
not significantly change total T levels. However, similar to 
earlier findings (8), free testosterone levels remained un- 
altered after nCPAP treatment. In the three subjects where 
both pre- and post-treatment SHBG values were available, 
almost identical values were found before and after treat- 
ment. Serum T and SHBG were positively correlated in the 
patients as well as in the controls. Circulating T and SHBG 
concentrations usually covariate in adult men, probably 
reflecting efforts to maintain a constant anabolic activity in 
the presence of changes in SHBG levels caused by, for 
example, alterations in nutritional state (32). Obesity is an 
extremely strong negative determinant of SHBG levels and 
consequently T levels are low in obese men (33). The 
discrepancy between our and other studies in pretreatment 
T levels may be explained by the inclusion of more severely 
diseased (8) OSAS patients in previous studies. BMI 
remained unaltered following nCPAP treatment in our 
patients. From this and from the unchanged SHBG levels 
in those where it was measured before and after treatment, 
it is reasonable to assume unchanged SHBG levels in 
the entire patient group. This is the probable reason for the 
unchanged total and free T levels in our study. The 
combination of subnormal LH levels in the presence of 
the normal androgen status found in our patients may 
suggest a resetting of the gonadostat, possibly at the 
hypothalamic level (8,9,34). 
There was no correlation between LH or total T on 
the one hand and basal or stimulated TSH on the other. 
This may indicate that OSAS affects the hypothalamic- 
pituitary-thyroid and hypothalamic-pituitary-testicular 
axes by different mechanisms. 
In conclusion, elevated catecholamine and cortisol levels 
were found in our group of OSAS patients in accordance 
with previous studies. In contrast to earlier investigations 
our patients had decreased TSH and LH levels but a 
normal response to TRH challenge and a normal androgen 
status. The decreased levels of catecholamines and reduced 
basal levels of TSH and prolactin following long-term 
nCPAP treatment probably reflect reduced chronic hypoxic 
stress as well as improved sleep quality. However, apart 
from catecholamines, it is less probable that any of the 
hormones studied serve as specific markers for chronic 
hypoxic stress. 
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